COLLABORATIONS AND INVESTMENT OPPORTUNITIES Nephrogenix currently has a number of collaborators and corporate alliances with commercial companies and research institutes. COLLABORATIONS The University of Queensland and Monash University Nephrogenix is a Queensland and Victorian based company bringing together leading Australian researchers from the University of Queensland and Monash University to enable a coordinated approach to conduct research and development of intellectual property for renal regeneration and therapeutics. The intellectual property developed by the Renal Regeneration Consortium is currently licensed to Nephrogenix from both The University of Queensland and Monash University. Websites: www.uq.edu.au and www.monash.edu.au IMBcom and Monash Commercial Nephrogenix is a spin out company of both IMBcom and Monash Commercial. IMBcom is the commercialisation company for the Institute for Molecular Bioscience (IMB) and promotes excellence in commercialisation within the Institute. Monash Commercial is the commercial company for Monash University and provides commercialisation services for the entire University. Websites: www.imbcom.com.au and www.monashcommercial.com Kidney Health Australia Kidney Health Australia currently funds a research program conducted by researchers within the renal Regeneration Consortium which aims to identify, define, isolate and expand renal stem cells. The long-term goal of this research is to induce Renal or non-renal stem cells to either regrow a kidney or repopulate a resident kidney. Whilst still at the early experimental stage, this work, if proven successful, could be a most significant and exciting advance in kidney therapy and ultimately lead to a decline in the number of people needing dialysis and transplantation. Kidney Health Australia provides a variety of grants and scholarships to support individuals and groups in Australia undertaking research into the causes, prevention and treatment of diseases of the kidneys and urinary tract. Website: www.kidney.org.au The Australian Stem Cell Centre Nephrogenix has entered into a collaborative agreement with the Australian Stem Cell Centre (ASCC). This agreement recognises the research synergies between Nephrogenix and the ASCC. Both Nephrogenix and the ASCC aim to foster the translation of cell based therapy research into clinical commercial outcomes. Both Nephrogenix and the ASCC's core focus is to build on Australia's existing expertise in cell based therapies and related platform technologies in various therapeutic areas to lay the foundations for delivering of therapies to patients. The ASCC is a major collaborative initiative including many of Australia’s leading academic researchers to develop innovative therapeutic products to treat a range of serious injuries and debilitating diseases. It was formed out of the ‘Backing Australia’s Ability’ initiative of the Australia Government. The focus of Nephrogenix on the development of therapies for renal repair or regeneration and repair coincides and synergies with the aims of the ASCC programs in cellular therapies for cardiac and hematological disorders. Website: www.nscc.edu.au POTENTIAL PARTNERSHIPS AND INVESTMENT OPPORTUNITIES Nephrogenix is actively pursuing value-creating partnerships with pharmaceutical and biotech companies. We offer a range of business models for partnering and would be delighted to explore options with you. Nephrogenix is also seeking investment from Venture Capital organizations. Please contact the Executive Officer, Michael Lusis for further details.